EUREPA V 1/0.2mg Tablet 10's

SA. Drug-Drug Interactions: Inform your physician if you are taking any of the following medicine before taking EUREPA V 1/0.2MG TABLET: 1. Insulin or other oral hypoglycemics (e.g., sulfonylureas): Interaction: Repaglinide and Voglibose can lower blood sugar, so when used together, the risk of excessive blood glucose lowering may increase. Effect: The combination may increase the risk of hypoglycemia (low blood sugar). 2.CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin): Interaction: Repaglinide is metabolized by CYP3A4 enzymes, and inhibitors of this enzyme can reduce its breakdown, leading to higher drug levels. Effect: It can increase the concentration of repaglinide in the blood, leading to an increased risk of hypoglycemia. 3.CYP3A4 Inducers (e.g., Rifampicin, Phenytoin): Interaction: It can increase the activity of CYP3A4 enzymes, which may cause repaglinide to be cleared from the body more quickly. Effect: It can reduce the blood levels of repaglinide, making it less effective and potentially leading to poor blood sugar control. 4.Beta-blockers (e.g., Metoprolol): Interaction: Repaglinide and Voglibose can lower blood sugar, so when used together, the risk of excessive blood glucose lowering may increase. Effect: Beta-blockers may mask symptoms of hypoglycemia (such as tachycardia) and increase the risk of severe hypoglycemia. 5.Anticoagulants (e.g.,Warfarin): Interaction: Warfarin may increase the effect of repaglinide, leading to a higher risk of hypoglycemia. Effect: Repaglinide may increase the anticoagulant effect of warfarin, increasing the risk of bleeding. SYNOPSIS Drug : Repaglinide, Voglibose Pharmacological Category : Antidiabetic agents Therapeutic Indication : Type-2 diabetes mellitus Dosage Forms : Tablet MORE INFORMATIONHow long will the effects of EUREPA V 1/0.2MG TABLET last in the body? Repaglinide and Voglibose generally provides a duration of action of about 4-8 hours, with Repaglinide acting more quickly to control blood sugar after meals and Voglibose helping to maintain steady blood sugar levels by slowing down carbohydrate absorption. This combined effect helps in controlling postprandial (after-meal) blood sugar spikes. It is commonly taken before meals to optimize the control of blood sugar levels. How fast EUREPA V 1/0.2MG TABLET act? When repaglinide and voglibose are combined into one tablet, the onset of action would generally be dictated by the faster-acting repaglinide, which starts working within 15-30 minutes. However, the overall effect may be a more gradual and sustained action, as voglibose will continue to work over a longer period by delaying the absorption of carbohydrates. Differences from Other Anti-Diabetic Medications: Aspect Repaglinide+Voglinose Other Common Drugs Class Alpha-glucosidase inhibitor + Meglitinide Analog Metformin (Biguanides), Sulfonylureas, etc. Target Action Reduces post-meal blood sugar spikes Targets fasting blood sugar or insulin action. Mechanism of Action Slows carbohydrate breakdown in the intestine Improves insulin sensitivity (e.g., Metformin) or increases insulin release (e.g., Sulfonylureas). Onset of Action Fast acting (works immediately after meals) Varies (depends on drug class and type). Ideal Use Case Effective for post-meal glucose control Broad glucose control (fasting & post-meal). Hypoglycemia Risk Minimal (unless combined with insulin/sulfonylureas) Higher with sulfonylureas and insulin. Side Effects Gastrointestinal issues (bloating, gas) Varies (e.g., hypoglycemia, weight gain). Advantages of EUREPA V 1/0.2MG TABLET Over Glyciphage G, Trivolib and Others antidiabetic agents: Focus on Post-Meal Control: Highly effective in patients with significant post-meal glucose spikes. Minimal Risk of Hypoglycemia: Unlike insulin secretagogues (e.g., sulfonylureas), it does not directly lower blood sugar, reducing the risk of dangerously low blood sugar levels. Weight Neutral: It does not cause weight gain, unlike other medications like sulfonylureas or thiazolidinediones. Fast-Acting: Works quickly when taken just before meals, making it suitable for targeted post-meal glucose control. Who Should Use EUREPA V 1/0.2MG TABLET? EUREPA V 1/0.2MG TABLET is ideal for: Patients with type 2 diabetes who experience high postprandial (post-meal) blood sugar spikes. Those looking for a medication with minimal hypoglycemia risk. Patients for whom other medications like metformin are insufficient or intolerable.